Biomea Fusion reports Q3 net loss of $28.4M, advances diabetes and oncology pipeline

Biomea Fusion, Inc.

2023-Q3 EPS reported -$2.46

Net loss of $28.4M for Q3 2023 vs $22.9M in Q3 2022; cash of $199.5M as of Sep 30, 2023.
COVALENT-111 expansion cleared; 84% of patients showed HbA1c reduction at Week 4; enrollment in ~200 type 2 diabetics.
IND cleared for COVALENT-112 (BMF-219) in type 1 diabetes; enrollment of 150 adults expected to start in Q4 2023.
Initial AML data: 2 CRs out of 5 patients with menin-dependent mutations at Dose Level 4; BMF-500 first patient dosed.
Appointed Juan Pablo Frías, M.D., as Chief Medical Officer to oversee diabetes clinical development.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.6

Biomea Fusion, Inc. reported financial results for the quarter ended September 30, 2023.

Period: the quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On October 30, 2023, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

Biomea Fusion, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-056335

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.